Trial
NCT04327700
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
National Cancer Institute (NCI); THERABIONIC INC.
Condition
Hepatocellular Carcinoma
Intervention
TheraBionic
Why stopped
Slow accruals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-05